1. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
- Author
-
Stamp, Lisa K, Chapman, Peter T, Barclay, Murray, Horne, Anne, Frampton, Christopher, Tan, Paul, Drake, Jill, and Dalbeth, Nicola
- Subjects
- *
CONFIDENCE intervals , *DOSE-effect relationship in pharmacology , *ETHNIC groups , *GOUT , *MINORITIES , *MULTIVARIATE analysis , *STATISTICS , *URIC acid , *MULTIPLE regression analysis , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *DISEASE duration , *ALLOPURINOL , *ODDS ratio , *THERAPEUTICS - Abstract
Objectives To determine factors that predict inadequate serum urate (SU) lowering response in a randomized controlled trial of allopurinol dose escalation (DE) in gout. Methods Participants undergoing allopurinol DE were classified as: complete response (CR)—reached target SU at month 9 and 12 of the DE phase or if still dose escalating at month 9 reached target SU by month 12; partial response (PR)—reached target at some stage but not fulfilling criteria for CR; or inadequate response (IR)—did not reach target SU at any time. Results IR was uncommon, occurring in 13/150 (8.7%), compared with 82 (54.7%) CR, and 55 (36.6%) PR. Mean (s. e. m.) SU was higher at the end of the 12-month DE in IR compared with both CR and PR groups; 7.6 (0.31) vs 5.01 (0.06) and 5.97 (0.17) mg/dl respectively (P < 0.001). In univariate analysis, compete responders tended to be older, be receiving less allopurinol, have longer gout duration and were more likely to be New Zealand (NZ) European ethnicity, compared with IR+PR. Using multi-variate logistic regression analysis, only longer duration of gout and NZ European ethnicity remained significant independent predictors of CR. Baseline SU ⩾ 8 mg/dl had a sensitivity of 69.2% and specificity of 85.1% in predicting IR. The odds ratio for an IR if baseline SU was ⩾8 mg/dl was 11.7 (95% CI 3.3, 41.2). Conclusion A minority of people with gout never reach target SU when allopurinol dose is increased in a treat-to-target manner. Approximately one-third of those with SU ⩾ 8mg/dl despite allopurinol ⩾300mg/d have an IR to DE. Trial registration Australian New Zealand Clinical Trails Registry, https://www.anzctr.org.au, ACTRN12611000845932. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF